Skip to main content
Browse Subject Areas

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Screening and treatment of familial hypercholesterolemia in a French sample of ambulatory care patients: A retrospective longitudinal cohort study


Background and aims

Untreated Familial Hypercholesterolemia (FH) leads to premature morbidity and mortality. In France, its epidemiology and management are understudied in ambulatory care. We described the clinical profile, pharmacological management, and clinical outcomes in a French sample of FH patients.


This was a retrospective longitudinal study on patients from The Health Improvement Network (THIN®) database in France, between October 2016-June 2019. Patients ≥18 years, with probable/definite FH based on the Dutch Lipid Clinic Network (DLCN) criteria were included. Baseline characteristics, lipid profile, lipid-lowering therapy (LLT), low-density lipoprotein-cholesterol (LDL-C) goal achievement; and disease management at 6-month of follow-up were analyzed.


116 patients with probable (n = 70)/definite (n = 46) FH were included (mean age:57.8±14.0 years; 56.0% women; 9.5% with personal history of cardiovascular events); 90 patients had data available at follow-up. At baseline, 77.6% of patients had LDL-C>190 mg/dL, 27.6% were not receiving LLTs, 37.9% received statins alone, 20.7% statins with other LLTs, and 7.7% other LLTs. High-intensity statins were prescribed to 11.2% of patients, 30.2% received moderate-intensity statins, and 8.6% low-intensity statins. Only 6.0% of patients achieved LDL-C goal. At 6-month of follow-up, statins discontinuation and switching were 22.7% and 2.3%, respectively. None of the patients received proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors at baseline nor follow-up.


Despite the existence of effective LLTs, FH patients are suboptimally-treated, do not achieve LDL-C goal, and exhibit worsened pharmacological management over time. Future studies with longer follow-up periods and assessment of factors affecting LDL-C management, including lifestyle and diet, are needed.


Familial Hypercholesterolemia (FH) is a group of inherited genetic defects resulting in lifelong elevated levels of low-density lipoprotein-cholesterol (LDL-C) [15]. FH is more common than previously believed [6, 7]. Worldwide, it affects 1 in 311 [6] to 313 [7] people of every race and ethnicity [1], making it one of the most common serious genetic disorders [5, 6]. In Europe, the prevalence of FH in the general population is estimated at 0.3% [6, 7]. In France, the most recent population surveys estimated the prevalence of FH at about 0.83% [8].

When left untreated, FH unequivocally put patients at increased risk for premature morbidity and mortality due to atherosclerotic cardiovascular disease (ASCVD) [1, 2, 5, 914]. The risk of cardiac disease among FH patients increases between 13 [2] and 22 folds [15] compared with the general population. Further, FH patients are predicted to have 3.9 times more lifetime cardiovascular (CV) events than non-FH patients with a similar risk profile [16].

Different guidelines and statements agree on the importance of early diagnosis and adequate treatment as cornerstones to prevent premature CVD and improve overall survival of patients [1719]. However, FH remains substantially underdiagnosed and undertreated [2]. In European countries, diagnosis rates range between 6% in Spain and 71% in the Netherlands, and these numbers seem to be overestimated [2]. Until now, late FH diagnosis remains the norm across all world regions, including Europe [20]. Further, a large body of evidence reports massive under-treatment of subjects with FH, including an insufficient dose of Lipid-Lowering Therapy (LLT), and late introduction of the treatment, when severe atherosclerosis had already developed [2123]. The Copenhagen General Population Study reports that only 48% of FH patients received statins [24].

A global call to action was initiated to recognize FH as a health priority, acknowledging that considerable gains to health are achievable through optimal diagnosis and treatment [3].

In France, there is no clear knowledge about FH, its epidemiology and management in-depth, as there is a lack of longitudinal information from large databases [8, 25]. In light of the scarcity of available data, we aimed to explore the clinical profile and pharmacological management in patients with FH using data from a large French sample in ambulatory care, with the ultimate goal of informing advancements in patient care and outcomes.

Materials and methods

Study design and source of data

This was a retrospective longitudinal study, based on a subset of patients from The Health Improvement Network (THIN®) database in France. THIN® is a large real-world medico-economic European database, powered by GERS Data, a Cegedim Health Data Division. It comprises fully anonymized and non-extrapolated electronic medical records (EMR) collected at the physicians-level and coded using the International Classification of Diseases, 10th Revision (ICD-10) codes. THIN® database includes information on prescribed medicines per patient, and those reimbursed by the French National Insurance Healthcare Fund (CNAM). Data were collected by 2,000 General Practitioners (GPs), 130 cardiologists, and 40 endocrinologists, receiving 5.5 million patients regularly in their community office.

The database obtained approval from the French National Data Protection Authority (CNIL) for data collection since 2002. As the study was a retrospective analysis using secondary anonymized patient data only, no additional ethical approval was needed.

Since 2016, physicians are alerted to LDL-C levels >190 mg/dL, suggesting a case of FH, and invited to complete the Dutch Lipid Clinic Network (DLCN) score. These criteria are validated to be used in daily practice to identify patients with FH who warrant aggressive treatment, their use is widespread across Europe [19, 26], and are recommended to establish the clinical diagnosis of FH by the European Atherosclerosis Society (EAS) [2, 19]. The DLCN is a composite score that predicts the likelihood of a patient having FH and allows the classification of patients into probability groups of FH, ranging from unlikely, to possible, probable, or definite FH diagnosis. It is based on a combination of five dimensions: 1) Family history, i.e. having a first-degree relative with known premature coronary heart disease (CHD), or a first-degree relative with known LDL-C >95th percentile by age and sex for country, or a first-degree relative with tendon xanthoma and/or corneal arcus, or a child <18 years with LDL-C >95th percentile by age and sex for country; 2) Clinical history corresponds to premature CHD or premature cerebral or peripheral vascular disease; 3) Physical examination confirming the presence of tendon xanthoma or corneal arcus in a person <45 years; 4) high LDL-C levels; and 5) Molecular genetic testing and the finding of a causative mutation, if available. Definite Unlikely FH is diagnosed with a score between 0 and 2 points, possible FH diagnosis can be made with a score between 3 and 5 points, probable FH diagnosis corresponds to a score between 6 and 8 points, and FH is diagnosed with a score higher than 8 points [2, 18].

Study population

Patients ≥18 years, with probable FH (6–8 points) or definite FH (>8 points) on the DLCN score at index date were included. The inclusion period extended between 01 October 2016 and 30 June 2019.

Study period

The index date was the date of the first recording of the DLCN score of the patient by the consented physician into the database. A two-year lookback period was used to collect baseline characteristics and treatments prescribed. However, the baseline assessment was based on the closest measurement prior to the index date. After the baseline assessment, the patient was followed-up for a period of 6 months.

Outcome measures

Baseline characteristics included: demographic characteristics (age and gender); clinical characteristics/laboratory measurements (lipid panel including total-cholesterol, LDL-C and triglycerides levels); basic CV risk factors (history of familial dyslipidemia, body mass index (BMI) calculated as weight in kg/height in m2, and comorbidities (diabetes defined as diagnosis of diabetes and/or prescription/reimbursement of at least 3 oral antidiabetic agents and/or insulin in the last 2 years; hypertension: defined as diagnosis of hypertension and/or blood pressure (BP) ≥140/90 mmHg; and CVD defined as diagnosis of at least one of the following: myocardial infarction, chronic ischemic heart disease, stable angina, unstable angina, ischemic stroke, carotid artery disease, transient ischemic attack, peripheral artery disease, abdominal aortic aneurysm); LLT defined as any single prescription of statins, ezetimibe, statin and ezetimibe in fixed or separate combinations, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, statin and PCSK9 inhibitors combinations, or other LLTs (nicotinic acid, fibrates, bile acid sequestrants); statins intensity, categorized into high, medium and low-intensity based on the American College of Cardiology and American Heart Association (ACC/AHA) guideline [27]; and LDL-C goal achievement defined as the number (%) of patients who achieved LDL-C goal (LDL-C <130 mg/dL in patients without CVD, and LDL-C <70 mg/dL in those with CVD) [14].

The outcomes consisted of disease management at 6-month of follow-up, categorized as LLT discontinuation (defined as any LLT prescription at index date but no LLT prescription at 6-month of follow-up), switching (defined as different LLT/combination of LLT prescribed during follow-up than the LLT prescribed at index date, i.e. drug or drugs at index date no longer used during follow-up), increase (defined as one or more new LLT started during follow-up with index drugs also still continued), decrease (defined as one or more LLT at index date no longer taken at follow-up, but one or more LLT at index date still continued), or no change (defined as no change in LLT drugs prescribed between index date and follow-up); and cumulative all-cause hospitalizations during the follow-up period.

Statistical considerations

All data were collected and analyzed at baseline and at the end of the 6-month of follow-up. Descriptive analyses were performed for all baseline characteristics and outcomes of interest. Continuous variables were described using mean, standard deviation (SD), median, quartiles and minimum and maximum values. Categorical variables were described using percentage and 95% confidence interval for each category.


Study population

The analysis included 45,487 patients with an LDL-C level >190 mg/dL. Of these, 1,098 subjects (2.4%) had a DLCN score completed between 01 October 2016 and 30 June 2019 (Fig 1). Patients with unlikely FH (n = 435) or possible FH (n = 547) DLCN scores were excluded. Therefore, at baseline, the study cohort included 116 patients with probable FH (n = 70) or definite FH (n = 46) DLCN scores; of whom ten (8.6%) had a genetic confirmation of their FH status. Physical stigmata of FH were detected in 19 patients (16.3%). Ninety patients (77.6%) had data available for the 6-month follow-up; of whom 58 patients (64.4%) had at least one contact with the physician during this period.

Fig 1. Flowchart of study subjects.

LDL-C, Low-density lipoprotein cholesterol; LLT, Lipid-lowering therapy; DLCN, Dutch Lipid Clinic Network; FH, Familial hypercholesterolemia. aAn unlikely FH refers to a DLCN score of 0 to 2 points. bA possible FH refers to a DLCN score of 3 to 5 points. cA probable FH refers to a DLCN score of 6 to 8 points. dA definite FH refers to a DLCN score of above 8 points.

The baseline characteristics of the cohort are shown in Table 1. Mean age was 57.8±14.0 years, 56.0% of the patients were women, and 56.0% had a family history of dyslipidemia. Within this cohort, 11.2% were obese, and 34.5% had at least one comorbidity; the most common comorbidity was hypertension (28.4%), followed by CVD (9.5%).

Table 1. Demographic characteristics and comorbidities of patients with probable or definite FH at baseline.

Fig 2 details the lipid panel of the study participants at baseline. Overall, 77.6% of patients had an LDL-C level >190 mg/dL; 5.2% had an LDL-C level >325 mg/dL. Only 10.3% had an LDL-C level <160 mg/dL, and 6.9% had an LDL-C level between 160 and 190 mg/dL. Of the cohort, 82.8% had a total-cholesterol level ≥200 mg/dL; 37.0% had a triglycerides level ≥150 mg/dL. Finally, just 6.0% of the cohort achieved LDL-C treatment goal at baseline.

Fig 2. Lipid panel of study subjects at baseline.

Min, Minimum; Max, Maximum; Q, Quartile. aNumber of days to index-date: For all patients: Min: 0; Q1: 5; Q2: 43; Q3: 287; Max: 726; For patients with Definite FH: Min: 0; Q1: 8.5; Q2: 51.5; Q3: 333.5; Max: 687; For patients with Probable FH: Min: 0; Q1: 5; Q2: 25; Q3: 229; Max: 726. bNumber of days to index-date: For all patients: Min: 0; Q1: 5.5; Q2: 43; Q3: 265.5; Max: 726; For patients with Definite FH: Min: 0; Q1: 15; Q2: 54; Q3: 347; Max: 687; For patients with Probable FH: Min: 0; Q1: 5; Q2: 22; Q3: 199; Max: 726. cNumber of days to index-date: For all patients: Min: 0; Q1: 6; Q2: 47.5; Q3: 310.5; Max: 726; For patients with Definite FH: Min: 0; Q1: 15; Q2: 84; Q3: 347; Max: 709; For patients with Probable FH: Min: 0; Q1: 5; Q2: 25; Q3: 297; Max: 726. dThe index date is the date of the first entry of the DLCN score of the patient by the consented physician into the database.

Change of clinical management during the follow-up period

Therapeutic management of FH patients is shown in Table 2. At baseline, 27.6% of the patients were not receiving any LLTs. While only 37.9% received statin monotherapy, 6.0% received ezetimibe alone, 20.7% were prescribed statins in combination with other LLTs (including 15.5% with ezetimibe and 5.2% with LLTs other than ezetimibe). Finally, 7.7% of the patients received a combination of LLTs other than statins. Regarding statin intensity, only 11.2% of the study subjects were treated with high-intensity statins, 30.2% received moderate-intensity statins, and 8.6% were prescribed low-intensity statins (statin intensity was unknown for 8.6% of patients). At 6-month of follow-up, the percentage of patients not receiving any LLT increased to 47.8%; the percentage of patients receiving statins only decreased to 27.8%, and the percentage of patients prescribed statins and ezetimibe decreased to 12.2%. Further, the percentage of patients treated with high-intensity statins decreased to 8.9%, and those prescribed moderate-intensity statins dropped from to 20.0%. None of the patients were prescribed PCSK9 inhibitors at baseline nor at 6-month of follow-up.

Table 2. Pharmacological management and clinical outcomes of patients with probable or definite FH, at baseline and at 6-month of follow-up.

Change in LLT prescription between baseline and follow-up is detailed in Fig 3, and S1 Table. The majority of patients (71.9%) without an LLT prescription at baseline maintained this status at follow-up. Around half of the patients (47.7%) receiving statins at baseline maintained this prescription at 6-month of follow-up, while 22.7% discontinued therapy, and only one patient (2.3%) was prescribed additional ezetimibe. More than half of the patients (55.6%) prescribed statins and ezetimibe at baseline maintained their status, while 5.6% stopped the treatment. Over time, statin users rarely switched therapies (2.3%), compared with those receiving a combination of statins and ezetimibe (11.1%) or other LLTs (14.3%).

Fig 3. LLT change status of patients with definite or probable FH at 6-month of follow-up.

Discontinued defined as any LLT prescription at index date but no LLT prescription at 6-month of follow-up. Switching defined as different LLT/combination of LLT prescribed during follow-up than the LLT prescribed at index date. Increase defined as one or more new LLT started during follow-up with index drugs also still continued. Decrease defined as one or more LLT at index date no longer taken at follow-up, but one or more LLT at index date still continued. No change defined as no change in LLT drugs prescribed between index date and follow-up.

More than half of the patients (53.8%) prescribed high-intensity statins at baseline maintained their status at 6-month of follow-up. Only 2.9% of those receiving moderate-intensity statins intensified their therapy at follow-up, while 42.9% maintained their baseline intensity. Ten percent of patients receiving low-intensity statins at baseline were prescribed a higher intensity at follow-up, while 30% kept their baseline intensity (S2 Table). During the follow-up period, only 3 patients (3.3%) were hospitalized.


To our knowledge, this is the first study in France to screen for FH in a cohort using ambulatory care EMR from a large database and to support GPs, and ambulatory cardiologists and endocrinologists in identifying those who need to be treated. Our results provide evidence on clinical profiles, pharmacological management, and LDL-C goal attainment in FH, thus informing care of this understudied patient-population in France.

Clinical profiles

Underdiagnosis of FH patients remains a universal finding [28, 29], and is assumed to be more frequent among young adults, as they are less likely to refer to their physicians [30]. Recently, numerous efforts have been made in France to improve the national diagnosis and management of FH [31, 32]. Our study specifically pinpoints this issue in France, as reported by other large studies [8, 25], and adds evidence about the important role of primary care in identifying patients with FH, as found elsewhere [3335]. Although being relatively young in age, patients included in our cohort study exhibit a cluster of CV risk factors, including poor LDL-C and triglycerides profiles at baseline, and a high level of comorbidities, all of which are known to be independently associated with CVD [36, 37], adding to the inherent CVD risk of FH [16], whether treated or not [38]; which was also shown in French patients [8]. It is worthy to note that in this study patients having a probable or definite FH were younger than those with unlikely or possible FH (mean age±SD: 57.8±14.0 vs. 61.5±12.6 years), and a greater proportion of them had LDL-C levels >190 mg/dL (77.6% vs. 67.0%) (S3 Table).

Pharmacological management

Our findings confirm that, despite this elevated CV risk, FH in France is undertreated, and when LLT is provided, the therapy is suboptimal. LLT prescription in this cohort is not in line with the national guidelines for standard practice [14], as well as the European guidelines [19] that recommend prescribing first-line high-intensity statins in combination with diet and lifestyle changes among patients with an LDL-C level >190 mg/dL to reduce it by 50%, and consider adding PCSK9 inhibitors if failed to attain the goal [14]. Despite the high-quality evidence of the safety, effectiveness, and tolerance of PCSK9 inhibitors and even though these agents are reimbursed in France (although not in all forms of FH), none of the patients included in this study were prescribed PCSK9 inhibitors at baseline nor follow-up. Underuse of this therapy is a missed opportunity for improving patient outcomes; this underuse might be caused by numerous reasons. First, the initial prescription of these agents is reserved for specialties in cardiology, endocrinology, diabetes and metabolic diseases or internal medicine, while in our study, the patients were mostly seen by GPs. Second, the initial reimbursement of PCSK9 inhibitors in France was published between January and February 2018, while our data collection ended in June 2019; thus, most physicians could not prescribe. Third, the reimbursement of PCSK9 inhibitors was restricted to homozygous FH patients, and heterozygous FH patients treated with LCL-C apheresis, at the time the study was conducted (the reimbursement of PCSK9 inhibitors for secondary prevention of CV events, independently of FH status, was published in July 2020). Fourth, underuse of these agents might only be due to the short duration of follow-up (6 months), as PCSK9 inhibitors are used as second line agents, after failure of therapy with statins alone.

Our findings are in line with the results of the third French MONICA and MONALISA population surveys among patients with probable or definite FH and underscore the issue of undertreatment of FH patients in France [8]. Also, our results add to the international literature regarding the universal issue of undertreatment of FH patients, whereby treatment with LLTs ranged between 25.8% [39] in Canada to 48% in Denmark [24], 53% in the Netherlands [40] and 84% in Spain [41]. Hence, LDL-C goal achievement ranged between 3.4% in Spain [41] and 23% [40] in the Netherlands.

Besides highlighting the massive undertreatment of this population, our findings provide evidence on a worsened pharmacological management and underutilization of LLT over time, and these results are more alarming that what was reported elsewhere. For instance, data from the national screening program in the Netherlands [42] showed an increase in LLT prescription from 39% to 93% one-year following the initial examination. Besides, during the 6-month follow-up period, only 77.5% of the initial cohort were retained for evaluation, as follow-up data were not available for 22.5% of the cohort. Generally, numerous barriers on the part of patients, their families, physicians, and health systems hinder the treatment of the disorder [17]. Besides underdiagnosis at baseline which hinders treatment initiation, undertreatment might be due to the relatively young age of our cohort, and the occurrence of adverse reactions [43, 44], two factors that are strongly associated with poor compliance with LLTs. Also, this may be due to the suboptimal knowledge of FH and its management, as well as the underestimation of its CV risk by physicians providing care to FH patients in France, as shown by a recent survey in a representative sample of physicians [4]. Possibly, within the context of the "French Paradox", French physicians think that patients with FH have a lower coronary artery disease risk than FH patients elsewhere [8]. Likewise, young FH patients perceive their vulnerability to CVD as low [45], which may affect their adherence to LLTs [46]. As undertreatment of FH is associated with unfavorable outcomes, increasing compliance with LLTs should become a major concern for physicians. Early and frequent follow-up by physicians, especially lipid testing, is associated with improved adherence to LLTs [47].

Strengths and limitations

This study uses real-world data from a national, large, established, and quality-assured database, where the information on FH was routinely and prospectively collected [48]. Using the DLCN criteria to diagnose FH is another strength of this study. Although genetic testing is the gold standard to ascertain the diagnosis of FH [14], recently, the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) recommend that FH should be diagnosed using clinical criteria and confirmed, when possible, via DNA analysis [19]. These criteria are most frequently used in population surveys in FH, as they show a good diagnostic and predictive value [26, 49, 50], and their use has been fostered among GPs [30]. Moreover, as the DLCN criteria were completed by the physician, the bias from missing values should be limited. Finally, we relied on prescribed and reimbursed medicines per patient.

On the other hand, based on the DLCN algorithm, a patient may obtain sufficient points to be categorized as a definite case solely from the non-LDL categories (family history, personal clinical history, physical exam). Besides, due to lack of time or by insufficient knowledge on FH and its risks by the physicians, selection bias may exist towards patients that are better followed-up by their physicians. Further, missing evaluation for some lifestyle factors limited the description of the characteristics of the patients included, and limited our ability to evaluate factors confounding the management of the patients. Additionally, there is the potential of misreporting of information in the existing health systems from where data are retrieved (EMR) as data are collected voluntarily. Moreover, familial combined hyperlipidemia or secondary causes of FH were not explored; the study did not entail molecular genetic testing to confirm FH status; hence all cases of probable/definite FH based on the DLCN score, irrespective of the cause, were included. This is a limitation of analyses using secondary patient data. Further, just as with all clinical database analyses, our findings dependent on the quality of information entered into the database. In some cases, incomplete or improper recording of some variables or diagnoses might take place, potentially leading to misclassification of some patients into subgroups. Due to the short-term duration of the study, we relied on surrogate outcomes and did not collect data on hard outcomes including mortality, and incidence recurrent CV events during follow-up (only all-cause hospitalizations during follow-up were reported). Also, data on LDL-C levels during follow-up were unavailable for the majority of patients, hindering our ability to assess attainment of treatment goal at follow-up. Besides, the short duration of the follow-up does not allow us to get the whole picture on second line treatment. Finally, our results may not be representative of the whole FH population in France, thus not be generalizable to this population.


To our knowledge, this is the first study to explore clinical profiles and pharmacological management of clinically-diagnosed FH patients, as specified in international guidelines, in primary care practice in France. This study provides evidence that the diagnosis of FH is possible within general medicine, and integral to the GPs’ activity; the latter are in the best position to identify patients before they manifest CV events. Also, our findings provide real-world evidence that FH patients in France are underdiagnosed, undertreated, and do not attain therapeutic LDL-C goals in ambulatory care settings, although effective therapy is available. Because of the debilitating clinical, societal and economic burden of untreated FH, it is imperative to escalate screening, and diagnosing of FH, intensify LLTs and make use of novel options such as PCSK9 inhibitors to reduce patients’ CV risk, improve their prognoses, and alleviate the disease’s burden.

Supporting information

S1 Table. LLT prescriptions of patients with definite or probable FH, at baseline and at month-6 of follow-upa.

LLT, Lipid-lowering therapy; FH, Familial hypercholesterolemia. aData are presented as n (%).


S2 Table. Statin intensity of patients with definite or probable FH, at baseline and at month-6 of follow-upa.

aData are presented as n (%). bAny statin, excluding statin + ezetimibe fixed combination. FH, Familial hypercholesterolemia.


S3 Table. Demographic and clinical characteristics and comorbidities of patients with definite, probable, possible or unlikely FH, at baselinea.

FH, Familial hypercholesterolemia; SD, Standard deviation; CI, Confidence interval; CVD, Cardiovascular disease; CIHD, Chronic ischemic heart disease; LDL, Low-density lipoprotein; Min, Minimum; Max, Maximum; Q, Quartile; LLT, Lipid lowering therapy. aThe index date is the date of the first entry of the DLCN score of the patient by the consented physician into the database. bAny statin, excluding statin + ezetimibe fixed combination.



Medical writing assistance was provided by Nadine Saleh (PharmD, PhD) of ESN for research assistance.


  1. 1. Gidding SS, Ann Champagne M, de Ferranti SD, Defesche J, Ito MK, et al. The agenda for familial hypercholesterolemia: a scientific statement from the American Heart Association. Circulation. 2015 Dec 1;132(22):2167–92. pmid:26510694
  2. 2. Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society. Eur Heart J. 2013 Dec 1;34(45):3478–90. pmid:23956253
  3. 3. Representatives of the Global Familial Hypercholesterolemia Community, Wilemon KA, Patel J, Aguilar-Salinas C, Ahmed CD, Alkhnifsawi M, et al. Reducing the Clinical and Public Health Burden of Familial Hypercholesterolemia: A Global Call to Action. JAMA Cardiol. 2020 Feb 1;5(2):217. pmid:31895433
  4. 4. Ferrières J, Bruckert é., Béliard S, Rabès J-P, Farnier M, Krempf M, et al. Hypercholestérolémie familiale: un risque cardiovasculaire largement sous-estimé. Ann Cardiol Angéiologie. 2018 Feb;67(1):1–8.
  5. 5. Goldberg AC, Hopkins PN, Toth PP, Ballantyne CM, Rader DJ, Robinson JG, et al. Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients. J Clin Lipidol. 2011 Jun;5(3):S1–8.
  6. 6. Hu P, Dharmayat KI, Stevens CAT, Sharabiani MTA, Jones RS, Watts GF, et al. Prevalence of Familial Hypercholesterolemia Among the General Population and Patients With Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-Analysis. Circulation. 2020 Jun 2;141(22):1742–59. pmid:32468833
  7. 7. Beheshti SO, Madsen CM, Varbo A, Nordestgaard BG. Worldwide Prevalence of Familial Hypercholesterolemia. J Am Coll Cardiol. 2020 May;75(20):2553–66. pmid:32439005
  8. 8. Bérard E, Bongard V, Haas B, Dallongeville J, Moitry M, Cottel D, et al. Prevalence and Treatment of Familial Hypercholesterolemia in France. Can J Cardiol. 2019 Jun;35(6):744–52. pmid:31151710
  9. 9. Ferrières J. Hypercholesterolaemia and coronary artery disease: A silent killer with several faces. Arch Cardiovasc Dis. 2019 Feb;112(2):75–8. pmid:30606472
  10. 10. Bianconi V, Banach M, Pirro M. Why patients with familial hypercholesterolemia are at high cardiovascular risk? Beyond LDL-C levels. Trends Cardiovasc Med [Internet]. 2020 Mar [cited 2020 Jul 24]; Available from: pmid:32205033
  11. 11. Béliard S, Millier A, Carreau V, Carrié A, Moulin P, Fredenrich A, et al. The very high cardiovascular risk in heterozygous familial hypercholesterolemia: Analysis of 734 French patients. J Clin Lipidol. 2016 Sep;10(5):1129–36.e3. pmid:27678429
  12. 12. Béliard S, Boccara F, Cariou B, Carrié A, Collet X, Farnier M, et al. High burden of recurrent cardiovascular events in heterozygous familial hypercholesterolemia: The French Familial Hypercholesterolemia Registry. Atherosclerosis. 2018 Oct;277:334–40. pmid:30270068
  13. 13. Séguro F, Rabès J-P, Taraszkiewicz D, Ruidavets J-B, Bongard V, Ferrières J. Genetic diagnosis of familial hypercholesterolemia is associated with a premature and high coronary heart disease risk. Clin Cardiol. 2018 Mar;41(3):385–91. pmid:29574850
  14. 14. Farnier M, Bruckert E, Boileau C, Krempf M. Diagnostic et traitement des hypercholestérolémies familiales (HF) chez l’adulte: recommandations de la Nouvelle société française d’athérosclérose (NSFA). La Presse Médicale. 2013 Jun 1;42(6):930–50.
  15. 15. Khera AV, Won H-H, Peloso GM, Lawson KS, Bartz TM, Deng X, et al. Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia. J Am Coll Cardiol. 2016 Jun;67(22):2578–89. pmid:27050191
  16. 16. Villa G, Wong B, Kutikova L, Ray KK, Mata P, Bruckert E. Prediction of cardiovascular risk in patients with familial hypercholesterolaemia. Eur Heart J—Qual Care Clin Outcomes. 2017 Oct 1;3(4):274–80. pmid:29044394
  17. 17. Alonso R, Perez de Isla L, Muñiz-Grijalvo O, Mata P. Barriers to Early Diagnosis and Treatment of Familial Hypercholesterolemia: Current Perspectives on Improving Patient Care. Vasc Health Risk Manag. 2020 Jan;Volume 16:11–25. pmid:32021224
  18. 18. McGowan MP, Hosseini Dehkordi SH, Moriarty PM, Duell PB. Diagnosis and Treatment of Heterozygous Familial Hypercholesterolemia. J Am Heart Assoc [Internet]. 2019 Dec 17 [cited 2020 Jul 24];8(24). Available from: pmid:31838973
  19. 19. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020 Jan 1;41(1):111–88.
  20. 20. Stock J. First insights from the EAS familial hypercholesterolaemia collaboration registry: FH is still underdiagnosed and undertreated. Atherosclerosis. 2019 Nov;290:138–9. pmid:31610884
  21. 21. Versmissen J, Oosterveer DM, Yazdanpanah M, Defesche JC, Basart DCG, Liem AH, et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ. 2008 Nov 11;337(nov11 1):a2423–a2423. pmid:19001495
  22. 22. Neil HA, Betteridge DJ, Broome K, Durrington PN, Hawkins MM, et al. Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Scientific Steering Committee on behalf of the Simon Broome Register Group. Atherosclerosis. 1999 Jan 5;142(1).
  23. 23. Huijgen R, Vissers MN, Defesche JC, Lansberg PJ, Kastelein JJ, Hutten BA. Familial hypercholesterolemia: current treatment and advances in management. Expert Rev Cardiovasc Ther. 2008 Apr 1;6(4):567–81. pmid:18402545
  24. 24. Benn M, Watts GF, Tybjaerg-Hansen A, Nordestgaard BG. Familial Hypercholesterolemia in the Danish General Population: Prevalence, Coronary Artery Disease, and Cholesterol-Lowering Medication. J Clin Endocrinol Metab. 2012 Nov 1;97(11):3956–64. pmid:22893714
  25. 25. Ferrières J, Combis MS, Verdier C, Genoux A, Gennero I, et al. Big data and lipoproteins: prevalence of dyslipidemias in 100 762 individuals. In European Heart Journal 2016 Aug 1 (Vol. 37, pp. 11–11). Great Clarendon St, Oxford, England: Oxford Univ Press.
  26. 26. Séguro F, Bongard V, Bérard E, Taraszkiewicz D, Ruidavets J-B, Ferrières J. Dutch Lipid Clinic Network low-density lipoprotein cholesterol criteria are associated with long-term mortality in the general population. Arch Cardiovasc Dis. 2015 Oct;108(10):511–8. pmid:26073227
  27. 27. Goff DC, Lloyd-Jones DM, Bennett G, Coady S, D’agostino RB, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Jul 1;63(25 Part B):2935–59.
  28. 28. Catapano AL, Lautsch D, Tokgözoglu L, Ferrieres J, Horack M, Farnier M, et al. Prevalence of potential familial hypercholesterolemia (FH) in 54,811 statin-treated patients in clinical practice. Atherosclerosis. 2016 Sep;252:1–8. pmid:27494444
  29. 29. De Backer G, Besseling J, Chapman J, Hovingh GK, Kastelein JJ, et al. Prevalence and management of familial hypercholesterolaemia in coronary patients: an analysis of EUROASPIRE IV, a study of the European Society of Cardiology. Atherosclerosis. 2015 Jul 1;241(1):169–75. pmid:25997074
  30. 30. Guglielmi V, Bellia A, Pecchioli S, Medea G, Parretti D, Lauro D, et al. What is the actual epidemiology of familial hypercholesterolemia in Italy? Evidence from a National Primary Care Database. Int J Cardiol. 2016 Nov;223:701–5. pmid:27568993
  31. 31. Rabès J-P, Béliard S, Carrié A. Familial hypercholesterolemia: experience from France. Curr Opin Lipidol. 2018 Apr;29(2):65–71. pmid:29389714
  32. 32. Vallejo-Vaz AJ, De Marco M, Stevens CAT, Akram A, Freiberger T, Hovingh GK, et al. Overview of the current status of familial hypercholesterolaemia care in over 60 countries—The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Atherosclerosis. 2018 Oct;277:234–55. pmid:30270054
  33. 33. Green P, Neely D, Humphries SE, the Medway FH Audit Steering Committee, Saunders T, Gray V, et al. Improving detection of familial hypercholesterolaemia in primary care using electronic audit and nurse-led clinics: Diagnosing FH in primary care. J Eval Clin Pract. 2016 Jun;22(3):341–8. pmid:26608940
  34. 34. Kirke AB, Barbour RA, Burrows S, Bell DA, Vickery AW, Emery J, et al. Systematic Detection of Familial Hypercholesterolaemia in Primary Health Care: A Community Based Prospective Study of Three Methods. Heart Lung Circ. 2015 Mar;24(3):250–6. pmid:25445428
  35. 35. Weng SF, Kai J, Andrew Neil H, Humphries SE, Qureshi N. Improving identification of familial hypercholesterolaemia in primary care: Derivation and validation of the familial hypercholesterolaemia case ascertainment tool (FAMCAT). Atherosclerosis. 2015 Feb;238(2):336–43. pmid:25555265
  36. 36. Pérez de Isla L, Alonso R, Mata N, Saltijeral A, Muñiz O, et al. Coronary heart disease, peripheral arterial disease, and stroke in familial hypercholesterolaemia: insights from the SAFEHEART Registry (Spanish Familial Hypercholesterolaemia Cohort Study). Arterioscler Thromb Vasc Biol. 2016 Sep;36(9):2004–10. pmid:27444203
  37. 37. Pérez de Isla L, Alonso R, Mata N, Fernández-Pérez C, Muñiz O, Díaz-Díaz JL, et al. Predicting Cardiovascular Events in Familial Hypercholesterolemia: The SAFEHEART Registry (Spanish Familial Hypercholesterolemia Cohort Study). Circulation. 2017 May 30;135(22):2133–44. pmid:28275165
  38. 38. Kruse G, Kutikova L, Wong B, Villa G, Ray KK, et al. Cardiovascular Disease Risk And Risk Factors Associated With Familial Hypercholesterolemia: A Systematic Review. Value Health. 2017 Oct 1;20(9):A606.
  39. 39. Allard MD, Saeedi R, Yousefi M, Frohlich J. Risk stratification of patients with familial hypercholesterolemia in a multi-ethnic cohort. Lipids Health Dis. 2014 Dec 1;13(1):65.
  40. 40. Kuiper JG, Sanchez RJ, Houben E, Heintjes EM, Penning-van Beest FJA, Khan I, et al. Use of Lipid-modifying Therapy and LDL-C Goal Attainment in a High-Cardiovascular-Risk Population in the Netherlands. Clin Ther. 2017 Apr;39(4):819–27.e1. pmid:28347514
  41. 41. Mata N, Alonso R, Badimón L, Padró T, Fuentes F, et al. Clinical characteristics and evaluation of LDL-cholesterol treatment of the Spanish Familial Hypercholesterolemia Longitudinal Cohort Study (SAFEHEART). Lipids Health Dis. 2011 Dec 1;10(1):94.
  42. 42. Umans-Eckenhausen MA, Defesche JC, Sijbrands EJ, Scheerder RL, Kastelein JJ. Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands. The Lancet. 2001 Jan 20;357(9251):165–8. pmid:11213091
  43. 43. Sik Kim Y, Sunwoo S, Ree Lee H, Mi Lee K, Woo Park Y, Cheol Shin H, et al. Determinants of non-compliance with lipid-lowering therapy in hyperlipidemic patients. Pharmacoepidemiol Drug Saf. 2002 Dec;11(7):593–600. pmid:12462137
  44. 44. Vinogradova Y, Coupland C, Brindle P, Hippisley-Cox J. Discontinuation and restarting in patients on statin treatment: prospective open cohort study using a primary care database. BMJ. 2016 Jun 28;i3305. pmid:27353261
  45. 45. Claassen L, Henneman L, Kindt I, Marteau TM, Timmermans DRM. Perceived Risk and Representations of Cardiovascular Disease and Preventive Behaviour in People Diagnosed with Familial Hypercholesterolemia: A Cross-sectional Questionnaire Study. J Health Psychol. 2010 Jan;15(1):33–43. pmid:20064882
  46. 46. Galema-Boers JMH, Lenzen MJ, van Domburg RT, Roeters van Lennep J, van Bruchem-van de Scheur GG, Sijbrands EJ, et al. Predicting non-adherence in patients with familial hypercholesterolemia. Eur J Clin Pharmacol. 2014 Apr;70(4):391–7. pmid:24449092
  47. 47. Benner JS, Tierce JC, Ballantyne CM, Prasad C, Bullano MF, Willey VJ, et al. Follow-up lipid tests and physician visits are associated with improved adherence to statin therapy. Pharmacoeconomics. 2004 Nov 1;22(3):13–23. pmid:15669150
  48. 48. Herrett E, Gallagher AM, Bhaskaran K, Forbes H, Mathur R, et al. Data Resource Profile: Clinical Practice Research Datalink (CPRD). Int J Epidemiol. 2015 Jun;44(3):827–36. pmid:26050254
  49. 49. Akioyamen LE, Genest J, Shan SD, Reel RL, Albaum JM, Chu A, et al. Estimating the prevalence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis. BMJ Open. 2017 Sep;7(9):e016461. pmid:28864697
  50. 50. Civeira F, Ros E, Jarauta E, Plana N, Zambon D, Puzo J, et al. Comparison of Genetic Versus Clinical Diagnosis in Familial Hypercholesterolemia. Am J Cardiol. 2008 Nov;102(9):1187–93.e1. pmid:18940289